TIME TO HEMATOLOGIC RECOVERY PREDICTS SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH FLUDARABIN, CYCLOPHOSPHAMIDE AND RITUXIMAB – 11 YEARS OF REAL‐WORLD EXPERIENCE

Saved in:
Bibliographic Details
Published inHematological oncology Vol. 39; no. S2
Main Authors Mata, A. V, Mesquita, I. P, Alves, D, Medeiros, J, Polo, B, Lopes, C, Costa, M. J, Martins, C, Esteves, G, Lacerda, J. F, Raposo, J
Format Journal Article
LanguageEnglish
Published Chichester Wiley Subscription Services, Inc 01.06.2021
Subjects
Chronic lymphocytic leukemia
Cyclophosphamide
Immunotherapy
Leukemia
Lymphatic leukemia
Monoclonal antibodies
Rituximab
Targeted cancer therapy
Online AccessGet full text

Cover

More Information
ISSN:0278-0232
1099-1069
DOI:10.1002/hon.17_2881